Quick Answer
Tarsus Pharmaceuticals, Inc. reported Diluted EPS of $1.59 per share (loss) for fiscal year 2025.
Tarsus Pharmaceuticals, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$1.59 | +48.2% |
| 2024 | -$3.07 | +33.5% |
| 2023 | -$4.62 | -83.3% |
| 2022 | -$2.52 | -276.1% |
| 2021 | -$0.67 | +84.5% |
| 2020 | -$4.32 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.30 | +50.8% | +37.5% |
| June 30, 2025 | -$0.48 | +45.5% | +25.0% |
| March 31, 2025 | -$0.64 | +36.6% | -4.9% |
| September 30, 2024 | -$0.61 | +52.3% | +30.7% |
| June 30, 2024 | -$0.88 | +24.8% | +12.9% |
| March 31, 2024 | -$1.01 | -14.8% | +21.1% |
| September 30, 2023 | -$1.28 | -52.4% | -9.4% |
| June 30, 2023 | -$1.17 | -387.5% | -33.0% |
- Tarsus Pharmaceuticals, Inc. showed an increase of +48.2% in Diluted EPS compared to the prior fiscal year.
- Over the 2020–2025 period, Tarsus Pharmaceuticals, Inc.’s diluted eps has grown by 63.2% (from $4.32 per share (loss) to $1.59 per share (loss)).
- The most recent figure is from Tarsus Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 23, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: